(go to content)

Castellano | Euskara | Français | English

 Imagen decorativa
DAR No 5: Methylnaltrexone (Relistor®) for opioid-induced constipation

Content tools

Share it

  • Meneame
  • Delicious
  • Twitter
  • Google
  • Facebook

Subcutaneous route instead of suppository or enema in terminal patients




  • The use of methylnaltrexone should be limited to palliative care patients treated with opioids and with no response to common laxatives.
  • Its main advantage is the avoidance of suppositories or enemas.
  • There is no data regarding use for more than 4 months, and therefore prolonged use is not advised.
  • Its cost is considerably higher than common treatments.
  • Its benefit-risk relation is only acceptable in patients with a life expectancy of one to six months.


    Conclusions:

    The use of methylnaltrexone should be limited to palliative care patients treated with opioids and with no response to common laxatives. Its main advantage is the avoidance of suppositories or enemas. Its benefit-risk relation is only acceptable in patients with a life expectancy of one to six months.

Enviar comentario

You can send us a comment or suggestion and we will respond to most frequently asked questions

Competing interests (complete this field only if you have competing interests)

 

 

 

 

Suggestions/Comments  

Government of Navarre

Contact us | Accessibility | Legal notice | Site map